|
|
| | Prasinezumab Basic information |
| Product Name: | Prasinezumab | | Synonyms: | Prasinezumab;Research Grade Prasinezumab;Prasinezumab (anti-Alpha-synuclein);Research Grade Prasinezumab(DHE22002) | | CAS: | 1960462-19-4 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![Prasinezumab Structure]() |
| | Prasinezumab Chemical Properties |
| form | Liquid | | color | Colorless to light yellow |
| | Prasinezumab Usage And Synthesis |
| Uses | Prasinezumab (PRX 002) is a humanized IgG1 monoclonal antibody directed against aggregated α-synuclein. Prasinezumab has the potential for Parkinson's disease research[1]. | | IC 50 | α-synuclein Aggregation | | References | [1] Gennaro Pagano, et al. A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson's Disease (PASADENA): Rationale, Design, and Baseline Data. Front Neurol. 2021 Oct 1;12:705407. DOI:10.3389/fneur.2021.705407 |
| | Prasinezumab Preparation Products And Raw materials |
|